硫酸氧钒毒性的核磁共振代谢组学方法研究

采用基于核磁共振(NMR)的代谢组学方法,结合生化指标分析及组织病理学检测,研究了具有类胰岛素活性的硫酸氧钒(VOSO4)对Wistar大鼠的毒性作用.通过不同剂量的VOSO4对Wistar大鼠连续灌胃给药16d,收集大鼠的血清和尿液,并采集样品的1H NMR谱进行多变量数据统计分析来辨识其特征代谢物,然后采用TICL(a web Tool for automatic Interpretation of Compound List)方法建立特征代谢物的代谢网络模型,分析受影响的主要代谢途径及其相互关系.研究结果表明:高剂量组(45mg/kg)和低剂量组(15mg/kg)的特征代谢物含量与对照组存在明显的差异;与对照组相比,高剂量和低剂量组血清中乳酸、肌氨酸酐以及牛磺酸等代谢物的含量增加,尿液中氧化三甲胺(TMAO)、肌酐、牛磺酸和甘氨酸等代谢物的含量增加,并呈现显著的剂量依赖关系;给药组中乙酸和琥珀酸的含量都降低.这些结果说明VOSO4可能影响大鼠体内的糖代谢、脂类代谢及肠道菌群代谢等多个代谢系统,高剂量的VOSO4会导致肝脏毒性和肾脏损伤.     

甲亢患者血清和尿液的核磁共振代谢组学研究

应用基于核磁共振(NMR)的代谢组学方法, 研究甲状腺功能亢进(简称甲亢)患者和健康人群的血清和尿液, 分析甲亢疾病的特征代谢物. 实验收集33个甲亢患者和17个健康志愿者的血清样品以及53个甲亢患者和58个健康志愿者的尿液样品, 采用多元统计分析方法研究甲亢组和对照组血清和尿液中的内源性代谢差异. 结果表明, 甲亢组血清中的胆碱、葡萄糖和三甲胺等物质的含量升高, 而VLDL, LDL和胆固醇等脂质以及乳酸、糖蛋白和丙氨酸等代谢物的含量下降; 甲亢组尿液中的葡萄糖、柠檬酸、牛磺酸以及肌氨酸等代谢物的含量升高, 而马尿酸、TMAO、甲酸和琥珀酸等代谢物的含量下降. 结果表明, 甲亢病不仅影响了糖类、脂类和蛋白质三大物质的代谢, 还对能量代谢、肝肠循环和肠道微生物等多个生理系统产生显著影响, 并且可能造成肝脏及肾脏等器官的损伤.     

基于气相色谱-质谱联用和图模型分析的脂代谢异常患者血浆代谢组学研究

利用气相色谱-质谱联用技术(GC-MS)和图模型分析方法,寻找脂代谢异常患者可能的血浆代谢标志物群。采用GC-MS技术对37例脂代谢异常患者和10例健康人的血浆样品进行分析,得到血浆代谢物的表达谱。偏最小二乘-判别分析(Partial least squares-discriminant analysis,PLS-DA)得分图可区分脂代谢异常患者与健康人,运用PLS-DA载荷图及t检验发现有9个代谢物在两组间存在显著性差异。经NIST谱库检索,它们分别为缬氨酸、甘氨酸、丙氨酸、焦谷氨酸、葡萄糖醛酸、半乳糖、甘露糖、亚油酸和甘油。在脂代谢异常患者血浆中,除甘油浓度显著高于健康人外,其余8种代谢物浓度均明显低于健康人。图模型分析结果发现这些代谢物与脂代谢异常临床常用诊断指标之间具有很好的相关性。它们可能是脂代谢异常疾病早期诊断和预后新的特异性代谢标志物群。     

基于气相色谱-质谱联用技术的痛风病人血清代谢特征分析

痛风是一组仅见于人类的异质性疾病,随着时间的推移,将导致慢性关节炎并逐渐致残。该研究将基于气相色谱-质谱联用技术(GC-MS)的代谢组学方法应用于痛风病人的血清代谢特征分析。首先利用GCMS获得痛风病人和健康人的血清代谢指纹图谱,采用多变量统计分析对所得数据进行分析。主成分分析(PCA)得分图显示,痛风病人与健康人的血清代谢谱有差异。通过偏最小二乘-判别分析(PLS-DA)对样品进行进一步分型,根据模型的变量重要性因子(VIP值)及非参数检验结果筛选差异代谢物。共筛选出43种可能与痛风相关的代谢物,并对其中22个变量进行结构鉴定,主要包括丙二醇、2,3-二羟基丁酸、2,4-二羟基丁酸、赤藓糖醇、苏糖醇、苏糖酸、阿拉伯糖醇、D-葡萄糖酸、肌醇、次黄嘌呤、尿酸、尿苷、3-羟基-3-甲基丁酸、鸟氨酸、吲哚-3-乳酸、单乙醇胺、甘油、甘油酸、月桂酸及亚油酸等代谢物。与健康人相比,痛风病人的糖代谢、核苷酸代谢、氨基酸代谢及脂类代谢均发生了明显的紊乱。这些结果将为痛风临床诊断及治疗提供重要依据。     

阳虚体质者血清和尿液的核磁共振代谢组学

采用基于核磁共振(NMR)的代谢组学方法研究了中医阳虚体质及平和体质(正常对照)的血清和尿液, 分析了阳虚体质的特征代谢物. 实验收集阳虚体质及平和体质各30人的血清及尿液样品, 采用多元统计分析方法研究了阳虚质组和对照组血清和尿液中的内源性代谢差异. 结果表明, 阳虚质血清中乳酸、 极低密度脂蛋白/低密度脂蛋白、N-乙酰糖蛋白、脂肪酸及不饱和脂肪酸的含量降低, 谷氨酰胺、葡萄糖、磷脂酰胆碱及高密度脂蛋白的含量增多; 尿液中肌酐的含量降低, 乳酸、二甲胺、柠檬酸及马尿酸的含量增多. 阳虚体质的潜在生物标志物的发现从代谢组学角度为个体差异提供了新的依据. 阳虚体质与平和体质存在能量代谢、脂代谢及糖代谢的差异以及相关脏腑功能的改变.     

气相色谱-质谱结合主成分分析方法用于鼻咽癌病人血清中代谢产物的定性定量分析

建立了气相色谱-质谱(GC-MS)同时测定鼻咽癌患者和健康人血清样本中多种代谢物的方法。采用肟化-硅烷化的两步衍生方法,利用DB-5MS毛细管柱程序升温法分离血清中的多种成分。利用NIST标准质谱库和标准品对尿液中的代谢物进行定性定量分析,共鉴定出氨基酸、糖类、脂肪酸、有机酸和酯类等28种内源性代谢物质;进而使用主成分分析(PCA)模式识别方法分析健康人和病人血清中代谢产物差异。结果表明,该方法简便快捷,易于操作,且灵敏度高,能够同时检测血清中的多种组分,且在主成分分析下有明显的分类,因此可为鼻咽癌的早期诊断和发病机制研究提供新的策略。     

五味子治疗大鼠糖尿病肾病作用机制的血清代谢组学研究

采用基于超高效液相色谱与串联四级杆飞行时间质谱仪(Ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry,UPLC/Q-TOF-MS)联用技术的代谢组学方法,通过分析大鼠血清内源性代谢物的变化,研究五味子治疗糖尿病肾病的作用机制。利用高脂高糖饲料喂养并腹腔注射链脲佐菌素(STZ)建立糖尿病大鼠模型。给药12周后,采用试剂盒方法测定尿蛋白、尿肌酐的含量,结果表明五味子水提取物可以显著降低模型动物的尿蛋白含量(p<0.05),对糖尿病大鼠肾病并发症具有一定的改善作用。采用UPLC/Q-TOF-MS方法分析了五味子对糖尿病肾病大鼠的血清代谢轮廓,分析了健康组、模型组和五味子给药组的大鼠血清,采用偏最小二乘法-判别分析(Partial least squares discriminant analysis,PLS-DA)进行数据分析。PLS-DA得分图显示健康组、模型组和五味子组的代谢轮廓有显著差别,根据正交偏最小二乘法-判别分析(Orthogonal partial least squares discriminant analysis,OPLS-DA)载荷图筛选,将对各组分离贡献大的化合物的串联质谱分析数据,经Human Metabolome Database(HMDB)等数据库检索,进行质谱信息匹配,鉴定出黄尿酸、油酰胺、棕榈酰胺、尿酸、5-羟基己酸、硫酸对甲酚、对甲酚葡萄糖苷酸7种内源性代谢物为生物标记物。研究结果表明五味子通过影响色氨酸代谢、嘌呤代谢、肠内菌代谢、脂肪酸代谢等通路对糖尿病肾病发挥治疗作用,其中嘌呤代谢、肠内菌代谢通路可能是五味子发挥治疗作用的重要途径。     

气相色谱-质谱法结合偏最小二乘-判别分析用于血清和血浆中代谢物的比较分析

建立了肟化-硅烷化衍生血清和血浆中代谢物的方法,结合气相色谱-质谱法,可实现有机酸、氨基酸、脂肪酸和胆固醇等多类代谢物的同时分析测定。方法学考察结果表明,该方法准确可靠,重复性、精密度和回收率良好,满足血清和血浆样本代谢物分析的要求。利用建立的方法,对40个健康人血清样本和34个健康人血浆样本中的代谢物进行对比分析。结果表明,吲哚-3-乙酸是血浆中特有的代谢物;共有的39个代谢物中,有32种在血清和血浆中的含量有显著性差异。采用偏最小二乘-判别分析(PLSDA)建立血清和血浆的判别模型,并筛选出了5种区分血清和血浆的重要代谢物,即磷酸、异亮氨酸、2,3,4-三羟基丁酸、柠檬酸和硬脂酸。研究结果为代谢组学研究中血清和血浆样本的选择提供了依据。     

基于液相色谱/电喷雾飞行时间质谱技术的结石症尿液代谢组学探讨

探索了一种简便的尿液样品前处理流程,通过反相液相色谱(RPLC)与亲水相互作用色谱(HILIC)相结合的高效液相色谱/电喷雾飞行时间质谱的联用技术(HPLC/ESI-TOFMS),建立了泌尿系结石症的尿液代谢组学模型,研究结石症患者尿液样品中的代谢物浓度水平与健康人对照组间的差异情况。采用主成分分析(PCA)及偏最小二乘法-判别分析(PLS-DA)等多变量数据分析方法,寻找结石症患者组和对照组之间的差异性代谢谱。模型结果显示:结石症患者尿液代谢物水平与健康对照组具有明显差异,寻找其中潜在的差异性标志物群组,有望将该模型用于泌尿系结石症的快速预测和诊断。     

正交信号校正在正常成人血清1H NMR谱的代谢组分析中的滤噪作用评价

观察、比较正交信号校正(OSC)滤噪前后, 用不同的模式识别方法对正常成人血清代谢组¹H NMR谱进行分析的效果, 以探讨NMR代谢组学技术应用于临床研究和疾病早期诊断的可行性. 78例正常成人在采血前按常规要求禁食8 h, 记录血清一维600 MHz氢谱后, 分别采用主成分分析(PCA)、偏最小二乘法-判别分析(PLS-DA)以及簇类的独立软模式法(SIMCA)对氢谱进行模式识别分析. 结果表明: 虽然采血前并无其它诸如饮食、生活方式、生理周期等方面的严格限制, 采用OSC 滤噪后, PLS-DA能够完全区分不同性别的血清氢谱, 其判别能力优于PCA和SIMCA. 而且采用OSC滤噪与文献报道的未经OSC处理的PLS-DA法获得的与性别分类有关的主要NMR积分区段基本相同. 从OSC去除不同数目的隐变量后所致的PLS-DA模型的性能改变可见: OSC去除两个隐变量时, 前两个隐变量的特征值明显比后面的大; 剩余残差为20.82%, 即去除了79.18%的X变量中与反应变量Y不相关的系统变异. 此时PLS-DA计算所得的隐变量个数为1; 而不使用OSC或用OSC去除一个隐变量时, PLS-DA所得的隐变量个数分别为3和2. 作为PLS-DA模型质量的评价指标, R2X表示PLS-DA模型计算所获得的隐变量反映自变量X的变异的百分比, R2Y则表示隐变量反映因变量Y的变异的百分比, Q2 (cum)为交叉验证后PLS-DA模型所获隐变量能够预测X和Y变异的累计百分比. R2X在OSC去除两个隐变量时达到最低值, 表明此时PLS-DA计算模型包含的系统变异最少; R2Y与Q2 (cum)都达到80%以上并趋于稳定, 说明OSC去除两个隐变量时PLS-DA模型的质量优良. 显然, OSC可去除饮食、环境等因素的影响, 降低临床样本的不均一性, 这对于NMR代谢组学技术应用于临床研究至关重要. OSC滤噪去除的隐变量个数应根据剩余残差、去除隐变量的特征值大小、PLS-DA模型计算所得的隐变量个数和反映模型质量的相关指标加以判断.     

Chromatographic determination of some biomarkers of liver cirrhosis and hepatocellular carcinoma in Egyptian patients

Metabolomics has been shown to be an effective tool for disease diagnosis, biomarker screening and characterization of biological pathways. A total of 140 subjects were included in this study; urine metabolomes of patients with liver cirrhosis (LC, n = 40), patients with hepatocellular carcinoma (HCC; n = 55) and healthy male subjects (n = 45) as a control group were studied. Gas chromatography/mass spectrometry‐based urine metabolomics profiles were investigated for all participants. Diagnostic models were constructed with a combination of marker metabolites, using principal components analysis and receiver operator characteristic curves. A total of 57 peaks could be auto‐identified of which 13 marker metabolites (glycine, serine, threonine, proline, urea, phosphate, pyrimidine, arabinose, xylitol, hippuric acid, citric acid, xylonic acid and glycerol) were responsible for the separation of HCC group from healthy subjects. Also, eight markers metabolites (glycine, serine, threonine, proline, citric acid, urea, xylitol and arabinose) showed significant differences between the LC group and healthy subjects. No significant difference was detected between HCC and LC groups regarding all these metabolites. Metabolomic profile using GC–MS established an optimized diagnostic model to discriminate between HCC patients and healthy subjects; also it could be useful for diagnosis of LC patients. However, it failed to differentiate between HCC and LC patients.     

多维色谱串联质谱分析肝癌患者血浆中的低丰度差异蛋白

建立了分析肝癌患者血浆中低丰度差异蛋白的新的多维色谱串联质谱方法.以5例肝细胞癌(HCC)患者血浆为研究对象,选用免疫亲和色谱Agilent MARS Spin Cartridge去除血浆中6种主要高丰度蛋白;离线RP-HPLC预分级血浆低丰度蛋白并收集差异表达蛋白组;液相色谱-芯片(HPLC-CHIP,包含一支纳升级Zorbax 300SB-C18富集柱和一支纳升级Zorbax 300SB-C18分析柱)富集、分离差异表达蛋白组胰酶酶解肽混合物,线性离子阱质谱在线分析,以Spectrum Mill MS Proteomics Workbench自动分析MS和MS/MS数据后在UniProtKB/SWISS-PORT数据库中进行搜索,鉴定得到27种差异蛋白,其中23种蛋白与各种疾病或肿瘤相关,IMP3、ARNT2和GRIP1可能成为诊断HCC的潜在生物标志物.     

Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method

Late diagnosis of hepatocarcinoma (HCC) is one of the most primary factors for the poor survival of patients. Thereby, identification of sensitive and specific biomarkers for HCC early diagnosis is of great importance in biological medicine to date. In the present study, serum metabolites of the HCC patients and healthy controls were investigated using the improved liquid chromatography–mass spectrometry (LC/MS). A wavelet-based method was utilized to find and align peaks of LC–MS. The characteristic peaks were selected by performing a two-sample t test statistics (p value <0.05). Clustering analysis based on principal component analysis showed a clear separation between HCC patients and healthy individuals. The serum metabolite, namely 1-methyladenosine, was identified as the characteristic metabolite for HCC. Moreover, receiver–operator curves were calculated with 1-methyladenosine and/or alpha fetal protein (AFP). The higher area under curve value was achieved in 1-methyladenosine group than AFP group (0.802 vs. 0.592), and the diagnostic model combining 1-methyladenosine with AFP exhibited significant improved sensitivity, which could identify those patients who missed the diagnosis of HCC by determining serum AFP alone. Overall, these results suggested that LC/MS-based metabonomic study is a potent and promising strategy for identifying novel biomarkers of HCC.     

Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry

Fecal metabolome of healthy humans and patients suffering from liver cirrhosis and hepatocellular carcinoma (HCC) were studied using ultra performance liquid chromatography coupled to quadrupole-time-of-flight mass spectrometry (UPLC/Q-TOF MS). Metabolic features detected by the method were then statistically treated using partial least squares to latent structure-discriminant analysis (PLS-DA) models to discriminate between healthy and diseased states. PLS-DA was also used to discriminate between cirrhosis and HCC stressed fecal metabolomes and to identify potential biomarkers for cirrhosis and HCC that are expressed at significantly different amounts in fecal metabolomes. Score plots of pattern recognition analysis distinguished liver cirrhosis and HCC patients from healthy humans. Based on the variable of importance in the project (VIP) values and S-plots, six metabolites were considered as potential biomarkers with a strong increase in lysophosphatidylcholines and a dramatic decrease in bile acids and bile pigments in patients with liver cirrhosis and HCC in comparison with healthy humans. Results demonstrate the potential of UPLC-MS as an efficient and convenient method that can be applied to screen fecal samples and aid in the early diagnosis of cirrhosis and hepatocellular carcinoma.     

Association between interleukin 6 promoter variants and chronic hepatitis B progression

Interleukin 6 (IL6) plays an essential role in the regulation of immune response to chronic disease. In this study, the three known single nucleotide polymorphisms (SNPs) in the IL6 promoter region were genotyped in a large chronic hepatitis B cohort to evaluate the effects of IL6 promoter variants. The single base extension method was used for this genotyping. Haplotypes were constructed by the three SNPs in IL6. Allele frequencies were compared for; i) patients with chronic hepatitis (CH) and chronic carriers vs. chronic hepatis patients with clinical evidence of liver cirrhosis (LC) (i.e., portal hypertension), ii) cirrhotic patients with hepatocellular carcinoma (HCC) vs. without HCC by logistic regression, and iii) with respect to the time intervals from the onset of infection to HCC. Results were analyzed by Cox relative hazard analysis on the assumption that all the patients were infected during early infancy. The frequencies of each SNP were 0.002 (IL6-597 G>A), 0.25 (IL6-572 C>G) and 0.002 (IL6-174 G>C), respectively, in the Korean population (n = 1,046). No significant associations were detected between IL6-572 C>G and chronic hepatitis B outcome in this study; i.e., LC occurrence on CH (OR = 0.16-1.27, P = 0.13- 0.71) and HCC occurrence on LC (OR = 1.04-1.23, P = 0.89-0.60) of heterozygotes and homozygotes for G allele in referent comparison to homozygotes for common allele (C/C genotype), and time interval to HCC (RH = 0.67-1.00; P = 0.14-0.99). In conclusion, there appeared to be no significant associations between IL6 promoter variants and disease outcome in chronic hepatitis B.     

Macromolecular Crowding Agents‐Assisted Imprinted Polymers For Analysis Of Glycocholic Acid In Human Plasma And Urine

Glycocholic acid (GCA) is a newly identified biomarker for hepatocellular carcinoma (HCC) patients. In this study, a method based on macromolecular crowding strategy has been applied for preparation of a molecularly imprinted polymer (MIP), which possesses high adsorption capacity for GCA. Polymethyl methacrylate was used as a macromolecular crowding agent, N‐(3‐aminopropyl)‐methacrylamide hydrochloride as a functional monomer and ethylene dimethacrylate as a cross‐linker. The morphology and binding characteristics of MIP were assessed by scanning electron microscopy and absorption experiments. The MIP was used as an adsorbent material to separate GCA, and the molecularly imprinted solid‐phase extraction (MISPE) was carefully optimized. The MISPE combined with high‐performance liquid chromatographic analysis was successfully used to determine the GCA in plasma and urine samples. When spiked levels ranged from 0.2 to 20 μmol L^?1, the recoveries were between 94.3 and 100.5%. As a proof of principle, this proposed method has been validated on a small subset of HCC patients (n = 10) and healthy volunteers (n = 10). The average GCA concentrations of HCC patients in plasma and urine were about 25 and 2.8 times than that of healthy volunteers. Copyright © 2016 John Wiley & Sons, Ltd.     

Analysis of urinary nucleosides as helper tumor markers in hepatocellular carcinoma diagnosis

Hepatocellular carcinoma (HCC) is a common neoplasm in Taiwan, for which early diagnosis is difficult and the prognosis is usually poor. HCC is usually diagnosed by abdominal sonography and serum alpha‐fetoprotein (AFP) detection. Modified nucleosides, regarded as indicators for the whole‐body turnover of RNAs, are excreted in abnormal amounts in the urine of patients with malignancies and can serve as tumor markers. We analyzed the excretion patterns of urinary nucleosides from 25 HCC patients and 20 healthy volunteers by high‐performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI‐MS/MS) under optimized conditions. The HPLC/ESI‐MS/MS approach with selective reaction monitoring (SRM) allowed for the sensitive determination of nucleosides in human urine samples. The mean levels of the urinary nucleosides adenosine, cytidine, and inosine were significantly higher in HCC patients than healthy volunteers (average of 1.78‐, 2.26‐, and 1.47‐fold, respectively). However, the mean levels of urinary 1‐methyladenosine, 3‐methylcytidine, uridine, and 2′‐deoxyguanosine were not significantly different. Combined with the determination of serum AFP levels, the higher levels of urinary adenosine, cytidine, and inosine may be additional diagnosis markers for HCC in Taiwanese patients. Copyright © 2009 John Wiley & Sons, Ltd.     

Metabonomics investigation of human urine after ingestion of green tea with gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry and (1)H NMR spectroscopy

A method using gas chromatography/mass spectrometry (GC/MS), liquid chromatography/mass spectrometry (LC/MS) and (1)H NMR with pattern recognition tools such as principle components analysis (PCA) was used to study the human urinary metabolic profiles after the intake of green tea. From the normalized peak areas obtained from GC/MS and LC/MS and peak heights from (1)H NMR, statistical analyses were used in the identification of potential biomarkers. Metabolic profiling by GC/MS provided a different set of quantitative signatures of metabolites that can be used to characterize the molecular changes in human urine samples. A comparison of normalized metabonomics data for selected metabolites in human urine samples in the presence of potential overlapping peaks after tea ingestion from LC/MS and (1)H NMR showed the reliability of the current approach and method of normalization. The close agreements of LC/MS with (1)H NMR data showed that the effects of ion suppression in LC/MS for early eluting metabolites were not significant. Concurrently, the specificity of detecting the stated metabolites by (1)H NMR and LC/MS was demonstrated. Our data showed that a number of metabolites involved in glucose metabolism, citric acid cycle and amino acid metabolism were affected immediately after the intake of green tea. The proposed approach provided a more comprehensive picture of the metabolic changes after intake of green tea in human urine. The multiple analytical approach together with pattern recognition tools is a useful platform to study metabolic profiles after ingestion of botanicals and medicinal plants.     

Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma

The aim of this study was to identify molecular markers associated with oncogenic differentiation in hepatocellular carcinoma (HCC). Using an unsupervised clustering method with a cDNA microarray, HCC (T) gene expression profiles and corresponding non-tumor tissues (NT) from 40 patients were analyzed. Of total 217 genes, 72 were expressed preferentially in HCC tissues. Among 186 differentially regulated genes, there were molecular chaperone and tumor suppressor gene clusters in the Edmondson grades I and II (GI/II) subclass compared with the liver cirrhosis (LC) subclass. The Edmondson grades III and IV (GIII/IV) subclass with a poor survival (P=0.0133) contained 122 differentially regulated genes with a cluster containing various metastasis- and invasion-related genes compared with the GI/II subclass. Immunohistochemical analysis revealed that ANXA2, one of the 72 genes preferentially expressed in HCC, was over-expressed in the sinusoidal endothelium and in malignant hepatocytes in HCC. The genes identified in the HCC subclasses will be useful molecular markers for the genesis and progression of HCC. In addition, ANXA2 might be a novel marker for tumor angiogenesis in HCC.